AR079055A1 - Procedimiento para la preparacion de dabigatran etexilato e intermediarios del mismo - Google Patents
Procedimiento para la preparacion de dabigatran etexilato e intermediarios del mismoInfo
- Publication number
- AR079055A1 AR079055A1 ARP100104246A ARP100104246A AR079055A1 AR 079055 A1 AR079055 A1 AR 079055A1 AR P100104246 A ARP100104246 A AR P100104246A AR P100104246 A ARP100104246 A AR P100104246A AR 079055 A1 AR079055 A1 AR 079055A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- preparation
- intermediaries
- procedure
- same
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 title 1
- 229960003850 dabigatran Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 2
- 229910052794 bromium Inorganic materials 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 239000000460 chlorine Substances 0.000 abstract 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
- C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
Abstract
Reivindicacion 1: Procedimiento para la preparacion de compuestos de la formula (1), caracterizado porque un compuesto de la formula (2) se hace reaccionar con un compuesto de la formula (3) en la cual, en los compuestos anteriores 1, 2 y 3, los radicales R1, R2 y R3 significan en cada caso, independientemente entre sí, alquilo(C1-6) y Hal = cloro o bromo. Reivindicacion 11: Compuesto 7, caracterizado porque ha sido preparado segun un procedimiento segun una de las reivindicaciones 1 a 9. Reivindicacion 12: Compuesto 8, caracterizado porque ha sido preparado segun un procedimiento segun la reivindicacion 10. Reivindicacion 13: Compuesto, caracterizado porque tiene la formula (3): en donde el radical R1 significa alquilo(C1-6). Reivindicacion 15: Compuesto caracterizado porque tiene la formula (2): en donde los radicales R2 y R3, en cada caso independientemente entre si, significan alquilo(C1-6) y Hal = cloro o bromo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09176369 | 2009-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079055A1 true AR079055A1 (es) | 2011-12-21 |
Family
ID=41683288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104246A AR079055A1 (es) | 2009-11-18 | 2010-11-17 | Procedimiento para la preparacion de dabigatran etexilato e intermediarios del mismo |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8399678B2 (es) |
| EP (1) | EP2501692B1 (es) |
| JP (1) | JP5746707B2 (es) |
| KR (1) | KR101802132B1 (es) |
| CN (1) | CN102612517B (es) |
| AR (1) | AR079055A1 (es) |
| AU (1) | AU2010321098B2 (es) |
| BR (1) | BR112012011689B8 (es) |
| CA (1) | CA2780715C (es) |
| CL (1) | CL2012001171A1 (es) |
| DK (1) | DK2501692T3 (es) |
| EA (1) | EA023117B1 (es) |
| ES (1) | ES2525112T3 (es) |
| IL (1) | IL219247A (es) |
| MX (1) | MX2012005358A (es) |
| NZ (1) | NZ599587A (es) |
| PH (1) | PH12012500954A1 (es) |
| PL (1) | PL2501692T3 (es) |
| TW (1) | TWI478912B (es) |
| WO (1) | WO2011061080A1 (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| MX2010010647A (es) * | 2008-03-28 | 2010-10-20 | Boehringer Ingelheim Int | Proceso para preparar formulaciones de dabigatran para administracion oral. |
| US8471033B2 (en) * | 2008-06-16 | 2013-06-25 | Boehringer Ingelheim International Gmbh | Method for producing an intermediate product of dabigatran etexilate |
| AU2009272796A1 (en) * | 2008-07-14 | 2010-01-21 | Boehringer Ingelheim International Gmbh | Method for manufacturing medicinal compounds containing dabigatran |
| PE20110431A1 (es) | 2008-11-11 | 2011-07-13 | Boehringer Ingelheim Int | Etexilato de dabigatran o una sal del mismo |
| US8399678B2 (en) | 2009-11-18 | 2013-03-19 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dabigatran etexilate |
| PE20121335A1 (es) | 2009-11-18 | 2012-10-12 | Plexxikon Inc | Compuestos derivados de amida como inhibidores de raf cinasas |
| US9006448B2 (en) | 2010-12-06 | 2015-04-14 | Msn Laboratories Private Limited | Process for the preparation of benzimidazole derivatives and its salts |
| EP2522662A1 (en) * | 2011-05-11 | 2012-11-14 | Medichem, S.A. | Dabigatran etexilate and related substances, processes and compositions, and use of the substances as reference standards and markers |
| US9273030B2 (en) | 2012-04-02 | 2016-03-01 | Msn Laboratories Private Limited | Process for the preparation of benzimidazole derivatives and salts thereof |
| CN103420994B (zh) * | 2012-05-24 | 2016-04-06 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
| CN103420982B (zh) * | 2012-05-24 | 2015-07-08 | 天津药物研究院 | 达比加群酯衍生物及其制备方法和用途 |
| CN103420984B (zh) * | 2012-05-24 | 2015-07-08 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
| CN102850326B (zh) * | 2012-06-19 | 2014-04-09 | 上海现代制药股份有限公司 | 一种达比加群酯中间体及其制备方法和应用 |
| CN102850327B (zh) * | 2012-06-19 | 2014-07-16 | 上海现代制药股份有限公司 | 一种制备达比加群酯的中间体及其制备方法和应用 |
| CN102850325B (zh) * | 2012-06-19 | 2014-03-26 | 上海现代制药海门有限公司 | 一种达比加群酯关键中间体的制备方法 |
| US9399616B2 (en) | 2012-10-22 | 2016-07-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of 4-aminobenzoamidine dihydrochloride |
| CA2907839C (en) * | 2013-03-25 | 2021-11-23 | Usv Limited | Synthesis of dabigatran |
| CN103224469A (zh) * | 2013-05-16 | 2013-07-31 | 上海应用技术学院 | 一种以含氟基团修饰的苯环为中心的达比加群酯类似物及其合成方法 |
| CN103288744A (zh) * | 2013-06-04 | 2013-09-11 | 上海应用技术学院 | 一种含氟基团修饰的达比加群酯类似物及其合成方法 |
| EP2835370A1 (en) | 2013-08-08 | 2015-02-11 | Medichem, S.A. | New crystals of dabigatran etexilate mesylate |
| CN104418805B (zh) * | 2013-09-11 | 2017-02-22 | 浙江海正药业股份有限公司 | 一种达比加群酯中间体及其制备方法和应用 |
| CN104003977B (zh) * | 2014-06-05 | 2016-04-13 | 雅本化学股份有限公司 | N-(2-氯甲基-1-甲基-1h-苯并咪唑-5-酰基)-n-(吡啶-2-基) -3-氨基丙酸乙酯的制备方法 |
| EP3165521B1 (en) | 2014-07-03 | 2019-01-16 | Shanghai Institute Of Pharmaceutical Industry | Method of preparing dabigatran etexilate intermediate and intermediate compound |
| CN105461688B (zh) * | 2014-08-26 | 2017-12-29 | 上海医药工业研究院 | 苯并咪唑化合物k的合成方法 |
| CN105523999B (zh) * | 2014-10-21 | 2020-04-24 | 重庆医药工业研究院有限责任公司 | 一种达比加群酯中间体的合成方法 |
| CN104447697B (zh) * | 2014-11-24 | 2016-08-24 | 蚌埠丰原医药科技发展有限公司 | 一种达比加群酯中间体的制备方法 |
| CN104910047B (zh) * | 2015-05-11 | 2017-06-06 | 常州市阳光药业有限公司 | 达比加群酯中间体的制备方法 |
| CN104987323B (zh) * | 2015-07-10 | 2017-08-22 | 浙江美诺华药物化学有限公司 | 一种达比加群酯的制备方法 |
| CN106554370A (zh) * | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 含有磷酸酯的达比加群衍生物及其制备方法和用途 |
| CN105348148B (zh) * | 2015-11-30 | 2017-12-26 | 山东新华制药股份有限公司 | 制备达比加群酯中间体缩合物的杂质的草酸盐的方法 |
| CN105566296A (zh) * | 2015-12-16 | 2016-05-11 | 蚌埠丰原医药科技发展有限公司 | 一种制备达比加群酯酰胺化杂质的方法 |
| CN105669651B (zh) * | 2016-03-07 | 2018-03-06 | 山东罗欣药业集团股份有限公司 | 一种甲磺酸达比加群酯的制备工艺 |
| CN105777622A (zh) * | 2016-04-13 | 2016-07-20 | 山东新华制药股份有限公司 | 制备达比加群酯中间体环化物的杂质的方法 |
| CN105732433A (zh) * | 2016-04-13 | 2016-07-06 | 山东新华制药股份有限公司 | 达比加群酯中间体缩合物的精制方法 |
| CN106083822B (zh) * | 2016-08-17 | 2018-09-11 | 本溪经济开发区博美医药新技术开发有限公司 | 一种甲磺酸达比加群酯中间体的制备方法 |
| CN106928195B (zh) * | 2017-03-29 | 2019-04-19 | 福建省微生物研究所 | 一种达比加群酯关键中间体的合成方法 |
| CN108640903A (zh) * | 2018-04-16 | 2018-10-12 | 宏冠生物药业有限公司 | 一种达比加群酯中间体的制备方法 |
| CN108373466B (zh) * | 2018-04-16 | 2020-04-10 | 宏冠生物药业有限公司 | 一种达比加群酯的制备方法 |
| CN108997316A (zh) * | 2018-08-17 | 2018-12-14 | 四川青木制药有限公司 | 一种达比加群酯的制备工艺 |
| CN111606885A (zh) * | 2020-06-18 | 2020-09-01 | 安徽鼎旺医药有限公司 | 一种达比加群酯甲磺酸盐及其制备方法 |
| CN114380797A (zh) * | 2021-12-27 | 2022-04-22 | 山东诚汇双达药业有限公司 | 一种达比加群酯的合成方法 |
| CN116102536A (zh) * | 2022-10-25 | 2023-05-12 | 浙江燎原药业有限公司 | 一种利用相转移催化剂制备达比加群酯的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE121699A1 (es) * | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| WO1999041231A1 (en) | 1998-02-17 | 1999-08-19 | Ono Pharmaceutical Co., Ltd. | Amidino derivatives and drugs containing the same as the active ingredient |
| DE19833105A1 (de) * | 1998-07-23 | 2000-01-27 | Boehringer Ingelheim Pharma | Substituierte Phenylamidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US6242466B1 (en) | 1998-07-23 | 2001-06-05 | Boehringer Ingelheim Pharma Kg | Substituted phenylamidines |
| EP1609784A1 (de) | 2004-06-25 | 2005-12-28 | Boehringer Ingelheim Pharma GmbH & Co.KG | Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen |
| WO2006070878A1 (ja) * | 2004-12-28 | 2006-07-06 | Astellas Pharma Inc. | カルボン酸誘導体またはその塩 |
| DE102005061623A1 (de) | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen |
| DE102005061624A1 (de) | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen |
| EP1956018A1 (de) | 2007-02-06 | 2008-08-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Herstellung eines Benzimidazolderivats |
| US20120276206A1 (en) | 2008-03-28 | 2012-11-01 | Boehringer Ingelheim International Gmbh | Method for manufacturing acid pellets |
| MX2010010647A (es) | 2008-03-28 | 2010-10-20 | Boehringer Ingelheim Int | Proceso para preparar formulaciones de dabigatran para administracion oral. |
| WO2009153214A1 (en) | 2008-06-16 | 2009-12-23 | Boehringer Ingelheim International Gmbh | Process for the manufacture of an intermediate in the synthesis of dabigatran |
| US8471033B2 (en) | 2008-06-16 | 2013-06-25 | Boehringer Ingelheim International Gmbh | Method for producing an intermediate product of dabigatran etexilate |
| AU2009272796A1 (en) | 2008-07-14 | 2010-01-21 | Boehringer Ingelheim International Gmbh | Method for manufacturing medicinal compounds containing dabigatran |
| US8399678B2 (en) | 2009-11-18 | 2013-03-19 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dabigatran etexilate |
-
2010
- 2010-11-04 US US12/939,521 patent/US8399678B2/en active Active
- 2010-11-06 AU AU2010321098A patent/AU2010321098B2/en active Active
- 2010-11-06 DK DK10773338.8T patent/DK2501692T3/da active
- 2010-11-06 BR BR112012011689A patent/BR112012011689B8/pt active IP Right Grant
- 2010-11-06 PL PL10773338T patent/PL2501692T3/pl unknown
- 2010-11-06 CN CN201080052215.8A patent/CN102612517B/zh active Active
- 2010-11-06 EP EP10773338.8A patent/EP2501692B1/de active Active
- 2010-11-06 WO PCT/EP2010/066959 patent/WO2011061080A1/de not_active Ceased
- 2010-11-06 MX MX2012005358A patent/MX2012005358A/es active IP Right Grant
- 2010-11-06 CA CA2780715A patent/CA2780715C/en active Active
- 2010-11-06 ES ES10773338.8T patent/ES2525112T3/es active Active
- 2010-11-06 PH PH1/2012/500954A patent/PH12012500954A1/en unknown
- 2010-11-06 KR KR1020127012713A patent/KR101802132B1/ko active Active
- 2010-11-06 EA EA201200741A patent/EA023117B1/ru not_active IP Right Cessation
- 2010-11-06 NZ NZ599587A patent/NZ599587A/en unknown
- 2010-11-06 JP JP2012539262A patent/JP5746707B2/ja active Active
- 2010-11-17 AR ARP100104246A patent/AR079055A1/es active IP Right Grant
- 2010-11-17 TW TW099139596A patent/TWI478912B/zh active
-
2012
- 2012-04-18 IL IL219247A patent/IL219247A/en active IP Right Grant
- 2012-05-04 CL CL2012001171A patent/CL2012001171A1/es unknown
-
2013
- 2013-02-15 US US13/768,350 patent/US8993770B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079055A1 (es) | Procedimiento para la preparacion de dabigatran etexilato e intermediarios del mismo | |
| AR065186A1 (es) | Ditiocarbamatos; procedimiento de preparacion; composicion colectora que los contiene; metodos para el beneficio de una mena mineral que comprende su uso como colectores de espuma de flotacion y procesos de flotacion de espuma, en el beneficio y recuperacion de valores metalicos tales como cobre, pl | |
| AR093659A1 (es) | Derivados ciclicos de nucleosidos y usos de los mismos | |
| CU24517B1 (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| CU20110235A7 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
| CO6852084A2 (es) | Nuevos compuestos sustituidos con halógeno | |
| CY1117878T1 (el) | Πυριδινo-2-αμιδια χρησιμα ως αγωνιστες του cb2 | |
| CR11162A (es) | Procesos para la produccion de pirazoles | |
| CU24411B1 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos | |
| CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
| CR20140301A (es) | Derivados de betulina | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| CO2017002253A2 (es) | Compuesto dirigido a il-23a y tnf-alfa | |
| EA201401054A1 (ru) | N-циклиламиды в качестве нематоцидов | |
| AR071833A1 (es) | Inhibidores de quinasas (limk2), composiciones que los comprenden y metodos para tratar o prevenir enfermedades | |
| UY33910A (es) | 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del SNC | |
| DOP2010000272A (es) | Nuevos derivados de carbazol inhibidores de hsp90, composiciones que los contienen y utilizacion | |
| CO6210751A2 (es) | Derivados de indolinona y procedimiento para su fabricacion | |
| CO6400223A2 (es) | Derivados de 6-(6-o-sustituido-triazolopiridazina-sulfanil)benzotiazoles y bencimidazoles : preparación, aplicación como medicamentos y utilización como inhibidores de met | |
| AR077080A1 (es) | Compuestos de 2,3-dihidro-1h-indeno | |
| ECSP109919A (es) | Compuesto de piridacina cristalina | |
| CR20170005A (es) | Derivados de insoindolina | |
| UY31388A1 (es) | Método para la producción de 2´-desoxi-5-azacitidina (decitabina) | |
| AR099237A1 (es) | Composiciones tensioactivas acuosas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |